2019 Membrane and Separation Technology Research Review

NEXT STORY
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
PREV STORY
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

L.A. Care Health Plan Selects Apollo Managed Care Criteria Guidelines

author_avatar
NASDAQ Market News

Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

author_avatar
NASDAQ Market News

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

author_avatar
NASDAQ Market News